Home › Research › Tau biomarkers
Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway
Knapskog AB, Engedal K, Braekhus A.. Alzheimer disease and associated disorders, 2016-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Although Alzheimer disease (AD) remains a clinical diagnosis, biomarkers are in use to support the diagnosis. Three cerebrospinal biomarkers, amyloid-β (Aβ), total tau (T-tau), and phospho tau (P-tau), reflect neuropathologic changes observed in AD patients. Objective The aim of this study was to explore the performance of the cerebrospinal fluid biomarkers used in a memory clinic setting.
What this study adds
Evidence grade: Low
The record lists 205 participants. This study explored how cerebrospinal fluid amyloid, total tau and phospho tau biomarkers performed in a Norwegian memory clinic, with diagnoses made blind to the fluid results. Reported effect size: 31.9%; 92.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Knapskog, A. B., Engedal, K., & Braekhus, A. (2016). Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway. Alzheimer disease and associated disorders. https://doi.org/10.1097/wad.0000000000000126
Vancouver
Knapskog AB, Engedal K, Braekhus A. Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway. Alzheimer disease and associated disorders. 2016. doi:10.1097/wad.0000000000000126. PMID: 26629677.
BibTeX
@article{knapskog2016-26629677,
author = {Knapskog, A. B. and Engedal, K. and Braekhus, A.},
title = {{Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway}},
journal = {Alzheimer disease and associated disorders},
year = {2016},
doi = {10.1097/wad.0000000000000126},
pmid = {26629677},
url = {https://doi.org/10.1097/wad.0000000000000126}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Three cerebrospinal biomarkers, amyloid-β (Aβ), total tau (T-tau), and phospho tau (P-tau), reflect neuropathologic changes observed in AD patients.
- Objective The aim of this study was to explore the performance of the cerebrospinal fluid biomarkers used in a memory clinic setting.
- Methods We included 205 patients who had been through a standardized examination including lumbar puncture.
- Diagnoses were made blind to the results of the spinal fluid analyses.
Why it matters
This study explored how cerebrospinal fluid amyloid, total tau and phospho tau biomarkers performed in a Norwegian memory clinic, with diagnoses made blind to the fluid results. It is about diagnostic test performance, not about treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants205
- Effect size31.9%; 92.5%
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 205 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 1 / 6 | Cited 0.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Anne Brækhus: h-index 27 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Oslo University Hospital: institution h-index 777 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26629677) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.